These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18536657)

  • 1. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
    Shafizadeh N; Ferrell LD; Kakar S
    Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
    Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
    Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma.
    Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions.
    Swanson BJ; Yearsley MM; Marsh W; Frankel WL
    Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of heat-shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma.
    Nguyen TB; Roncalli M; Di Tommaso L; Kakar S
    Mod Pathol; 2016 Mar; 29(3):283-92. PubMed ID: 26769138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
    Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
    Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 5 Immunohistochemical Markers of Hepatocellular Differentiation for the Diagnosis of Hepatocellular Carcinoma.
    Nguyen T; Phillips D; Jain D; Torbenson M; Wu TT; Yeh MM; Kakar S
    Arch Pathol Lab Med; 2015 Aug; 139(8):1028-34. PubMed ID: 26230595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
    DU JL; Wei LX; Wang YL
    Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
    Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
    Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
    Choi WT; Kakar S
    Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions.
    Tátrai P; Somorácz A; Batmunkh E; Schirmacher P; Kiss A; Schaff Z; Nagy P; Kovalszky I
    Am J Surg Pathol; 2009 Jun; 33(6):874-85. PubMed ID: 19194276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.
    Zhu ZW; Friess H; Wang L; Abou-Shady M; Zimmermann A; Lander AD; Korc M; Kleeff J; Büchler MW
    Gut; 2001 Apr; 48(4):558-64. PubMed ID: 11247902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value.
    Wachter DL; Kristiansen G; Soll C; Hellerbrand C; Breuhahn K; Fritzsche F; Agaimy A; Hartmann A; Riener MO
    Histopathology; 2012 Jan; 60(2):278-86. PubMed ID: 22211286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions.
    Wasfy RE; Shams Eldeen AA
    Asian Pac J Cancer Prev; 2015; 16(11):4769-75. PubMed ID: 26107238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
    Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
    Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma arising in adenoma: similar immunohistochemical and cytogenetic features in adenoma and hepatocellular carcinoma portions of the tumor.
    Kakar S; Grenert JP; Paradis V; Pote N; Jakate S; Ferrell LD
    Mod Pathol; 2014 Nov; 27(11):1499-1509. PubMed ID: 24743216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Immunohistochemistry in the Pathological Diagnosis of Liver Tumors.
    Takahashi Y; Dungubat E; Kusano H; Ganbat D; Tomita Y; Odgerel S; Fukusato T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudins and tricellulin in fibrolamellar hepatocellular carcinoma.
    Patonai A; Erdélyi-Belle B; Korompay A; Somorácz A; Straub BK; Schirmacher P; Kovalszky I; Lotz G; Kiss A; Schaff Z
    Virchows Arch; 2011 Jun; 458(6):679-88. PubMed ID: 21503766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
    Ibrahim TR; Abdel-Raouf SM
    Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.